KRON Kronos Bio Inc
Price (delayed)
$0.9308
Market cap
$56.12M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.74
Enterprise value
$11.02M
Kronos Bio is a clinical-stage biopharmaceutical company dedicated to discovering and developing therapies that seek to transform the lives of those affected by cancer. The company focuses on targeting dysregulated
Highlights
The company's revenue has surged by 173% YoY and by 11% QoQ
Kronos Bio's gross profit has soared by 173% YoY and by 11% from the previous quarter
Kronos Bio's quick ratio has decreased by 17% YoY but it has increased by 3% from the previous quarter
The equity has declined by 39% year-on-year and by 10% since the previous quarter
Key stats
What are the main financial stats of KRON
Market
Valuations
Earnings
Shares outstanding
60.29M
Market cap
$56.12M
Enterprise value
$11.02M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.45
Price to sales (P/S)
6.65
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.31
Revenue
$8.41M
EBIT
-$102.85M
EBITDA
-$97.96M
Free cash flow
-$88.09M
Per share
Balance sheet
Liquidity
EPS
-$1.74
Free cash flow per share
-$1.47
Book value per share
$2.05
Revenue per share
$0.14
TBVPS
$2.73
Total assets
$164.27M
Total liabilities
$41.13M
Debt
$27.13M
Equity
$123.15M
Working capital
$124.55M
Debt to equity
0.22
Current ratio
8.49
Quick ratio
8.33
Net debt/EBITDA
0.46
Margins
Efficiency
Dividend
EBITDA margin
-1,164.7%
Gross margin
100%
Net margin
-1,222.8%
Operating margin
-1,321.9%
Return on assets
-51.5%
Return on equity
-68.8%
Return on invested capital
-71.1%
Return on capital employed
-69.7%
Return on sales
-1,222.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
KRON stock price
How has the Kronos Bio stock price performed over time
Intraday
-1.28%
1 week
-3.03%
1 month
-6.86%
1 year
-27.84%
YTD
-25.54%
QTD
-24.94%
Financial performance
How have Kronos Bio's revenue and profit performed over time
Revenue
$8.41M
Gross profit
$8.41M
Operating income
-$111.19M
Net income
-$102.85M
Gross margin
100%
Net margin
-1,222.8%
The company's revenue has surged by 173% YoY and by 11% QoQ
Kronos Bio's gross profit has soared by 173% YoY and by 11% from the previous quarter
The net margin has soared by 69% YoY and by 20% QoQ
The operating margin has soared by 68% year-on-year and by 20% since the previous quarter
Growth
What is Kronos Bio's growth rate over time
Valuation
What is Kronos Bio stock price valuation
P/E
N/A
P/B
0.45
P/S
6.65
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.31
Kronos Bio's EPS has increased by 18% YoY and by 13% QoQ
The equity has declined by 39% year-on-year and by 10% since the previous quarter
KRON's P/B is 8% below its last 4 quarters average of 0.5
The company's revenue has surged by 173% YoY and by 11% QoQ
KRON's P/S is 46% below its last 4 quarters average of 12.4
Efficiency
How efficient is Kronos Bio business performance
Kronos Bio's return on sales has surged by 69% YoY and by 20% QoQ
The company's return on invested capital fell by 39% YoY and by 7% QoQ
The ROE fell by 35% YoY
Kronos Bio's ROA has decreased by 25% YoY
Dividends
What is KRON's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for KRON.
Financial health
How did Kronos Bio financials performed over time
The total assets has declined by 37% year-on-year and by 10% since the previous quarter
The total liabilities is down by 28% year-on-year and by 11% since the previous quarter
The debt is 78% lower than the equity
Kronos Bio's debt to equity has increased by 47% YoY and by 10% from the previous quarter
The equity has declined by 39% year-on-year and by 10% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.